Ian Butterworth

Ian Butterworth is the Cofounder and Chief Technology Officer (CTO) at Leuko, a company focused on developing non-invasive white cell monitoring technology for chemotherapy patients.12 Here are some key details about his background and experience:

Professional Experience

At Leuko: Ian has been serving as the Cofounder and CTO since August 2017.2 In this role, he drives scientific research projects in various health areas and is described as a measurement systems expert who has developed hardware and software for four prior medical device startups.3

Previous Roles:

• Research Engineer / M+Vision Senior Biomedical Research Fellow at Massachusetts Institute of Technology (MIT) from July 2013 to December 20192
• Higher Research Scientist at the National Physical Laboratory from November 2008 to June 20132
• Assistant Acoustic Consultant at Hann Tucker Associates for a brief period in 20082

Education

• MSc in Audio Acoustics from the University of Salford (2007-2008)2
• BEng in Electronic Engineering from the University of Warwick (2004-2007)2

Expertise and Focus

Ian's work primarily revolves around:

• Biomedical and industrial research in emerging technologies2
• Non-invasive health monitoring for specific conditions2
• Acoustic measurement, industrial and medical ultrasound, and related fields2

At Leuko, Ian and his team are working on improving the quality of life and outcomes for chemotherapy patients and others at risk of severe neutropenia through the development of the first non-invasive white cell monitor.3